# Matter Neuroscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/matter-neuroscience

- Industry: Healthcare Specialists
- Headquarters: Boulder, US
- Website: www.matter.xyz
- Total disclosed funding: $19M
- Latest round: Series B (Nov 3, 2022)
- Investors on record: 4

## About

Based in Colorado, US, and co-founded by Axel Bouchon, Ben Goldhirsh, and Chris Shiflett in 2019, Matter Neuroscience Inc. operates as a healthcare company that specializes in developing treatment for neurological disorders. In February 2024, the firm raised USD 26 million in venture funding co-led by investors Exor Ventures, ARCH Venture Partners, along with the participation from other investors Polaris Partners and Collaborative Fund.

The company provides personalized information on the brain chemistry of patients and develops treatments for brain disorders. Matter Neuroscience, also identifies the biomarkers for happiness. The firm offers an application, that utilizes molecular-level insights on dopamine, oxytocin, and cannabinoids, to help users understand how experiences influence neurotransmitter activity in their brains. By capturing and reflecting on positive experiences, Matter aims to foster neuroplasticity for personal growth, creativity, and empathy. Long-term goals include correlating higher neuroplasticity levels with enhanced well-being and longevity.

The company plans to utilize the February 2024 funding to launch its consumer app and bolster its efforts to develop solutions to resolve the unhappiness epidemic through enhanced understanding and management of mental well-being.

## Funding rounds

- Series B, Nov 3, 2022, $19M — ARCH Venture Partners, Polaris Partners, Collaborative Fund, Exor Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B
- Collaborative Fund (https://capitalatlas.ai/funds/collaborative-fund) — Series B
- Exor Ventures — Series B